Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: The lung health study

Paul D. Scanlon, John E. Connett, Lance A. Waller, Murray D. Altose, William C. Bailey, A (Sonia) Buist, Donald P. Tashkin

Research output: Contribution to journalArticle

557 Citations (Scopus)

Abstract

Previous studies of lung function in relation to smoking cessation have not adequately quantified the long-term benefit of smoking cessation, nor established the predictive value of characteristics such as airway hyperresponsiveness. In a prospective randomized clinical trial at 10 North American medical centers, we studied 3,926 smokers with mild-to-moderate airway obstruction (3,818 with analyzable results; mean age at entry, 48.5 yr; 36% women) randomized to one of two smoking cessation groups or to a nonintervention group. We measured lung function annually for 5 yr. Participants who stopped smoking experienced an improvement in FEV1 in the year after quitting (an average of 47 ml or 2%). The subsequent rate of decline in FEV1 among sustained quitters was half the rate among continuing smokers, 31 ± 48 versus 62 ± 55 ml (mean ± SD), comparable to that of never-smokers. Predictors of change in lung function included responsiveness to β-agonist, baseline FEV1, methacholine reactivity, age, sex, race, and baseline smoking rate. Respiratory symptoms were not predictive of changes in lung function. Smokers with airflow obstruction benefit from quitting despite previous heavy smoking, advanced age, poor baseline lung function, or airway hyperresponsiveness.

Original languageEnglish (US)
Pages (from-to)381-390
Number of pages10
JournalAmerican Journal of Respiratory and Critical Care Medicine
Volume161
Issue number2 I
StatePublished - 2000
Externally publishedYes

Fingerprint

Smoking Cessation
Chronic Obstructive Pulmonary Disease
Lung
Health
Smoking
Methacholine Chloride
Airway Obstruction
Randomized Controlled Trials

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease : The lung health study. / Scanlon, Paul D.; Connett, John E.; Waller, Lance A.; Altose, Murray D.; Bailey, William C.; Buist, A (Sonia); Tashkin, Donald P.

In: American Journal of Respiratory and Critical Care Medicine, Vol. 161, No. 2 I, 2000, p. 381-390.

Research output: Contribution to journalArticle

Scanlon, Paul D. ; Connett, John E. ; Waller, Lance A. ; Altose, Murray D. ; Bailey, William C. ; Buist, A (Sonia) ; Tashkin, Donald P. / Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease : The lung health study. In: American Journal of Respiratory and Critical Care Medicine. 2000 ; Vol. 161, No. 2 I. pp. 381-390.
@article{f6efddc503b14a78bbc97cf9b73bb952,
title = "Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease: The lung health study",
abstract = "Previous studies of lung function in relation to smoking cessation have not adequately quantified the long-term benefit of smoking cessation, nor established the predictive value of characteristics such as airway hyperresponsiveness. In a prospective randomized clinical trial at 10 North American medical centers, we studied 3,926 smokers with mild-to-moderate airway obstruction (3,818 with analyzable results; mean age at entry, 48.5 yr; 36{\%} women) randomized to one of two smoking cessation groups or to a nonintervention group. We measured lung function annually for 5 yr. Participants who stopped smoking experienced an improvement in FEV1 in the year after quitting (an average of 47 ml or 2{\%}). The subsequent rate of decline in FEV1 among sustained quitters was half the rate among continuing smokers, 31 ± 48 versus 62 ± 55 ml (mean ± SD), comparable to that of never-smokers. Predictors of change in lung function included responsiveness to β-agonist, baseline FEV1, methacholine reactivity, age, sex, race, and baseline smoking rate. Respiratory symptoms were not predictive of changes in lung function. Smokers with airflow obstruction benefit from quitting despite previous heavy smoking, advanced age, poor baseline lung function, or airway hyperresponsiveness.",
author = "Scanlon, {Paul D.} and Connett, {John E.} and Waller, {Lance A.} and Altose, {Murray D.} and Bailey, {William C.} and Buist, {A (Sonia)} and Tashkin, {Donald P.}",
year = "2000",
language = "English (US)",
volume = "161",
pages = "381--390",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "2 I",

}

TY - JOUR

T1 - Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease

T2 - The lung health study

AU - Scanlon, Paul D.

AU - Connett, John E.

AU - Waller, Lance A.

AU - Altose, Murray D.

AU - Bailey, William C.

AU - Buist, A (Sonia)

AU - Tashkin, Donald P.

PY - 2000

Y1 - 2000

N2 - Previous studies of lung function in relation to smoking cessation have not adequately quantified the long-term benefit of smoking cessation, nor established the predictive value of characteristics such as airway hyperresponsiveness. In a prospective randomized clinical trial at 10 North American medical centers, we studied 3,926 smokers with mild-to-moderate airway obstruction (3,818 with analyzable results; mean age at entry, 48.5 yr; 36% women) randomized to one of two smoking cessation groups or to a nonintervention group. We measured lung function annually for 5 yr. Participants who stopped smoking experienced an improvement in FEV1 in the year after quitting (an average of 47 ml or 2%). The subsequent rate of decline in FEV1 among sustained quitters was half the rate among continuing smokers, 31 ± 48 versus 62 ± 55 ml (mean ± SD), comparable to that of never-smokers. Predictors of change in lung function included responsiveness to β-agonist, baseline FEV1, methacholine reactivity, age, sex, race, and baseline smoking rate. Respiratory symptoms were not predictive of changes in lung function. Smokers with airflow obstruction benefit from quitting despite previous heavy smoking, advanced age, poor baseline lung function, or airway hyperresponsiveness.

AB - Previous studies of lung function in relation to smoking cessation have not adequately quantified the long-term benefit of smoking cessation, nor established the predictive value of characteristics such as airway hyperresponsiveness. In a prospective randomized clinical trial at 10 North American medical centers, we studied 3,926 smokers with mild-to-moderate airway obstruction (3,818 with analyzable results; mean age at entry, 48.5 yr; 36% women) randomized to one of two smoking cessation groups or to a nonintervention group. We measured lung function annually for 5 yr. Participants who stopped smoking experienced an improvement in FEV1 in the year after quitting (an average of 47 ml or 2%). The subsequent rate of decline in FEV1 among sustained quitters was half the rate among continuing smokers, 31 ± 48 versus 62 ± 55 ml (mean ± SD), comparable to that of never-smokers. Predictors of change in lung function included responsiveness to β-agonist, baseline FEV1, methacholine reactivity, age, sex, race, and baseline smoking rate. Respiratory symptoms were not predictive of changes in lung function. Smokers with airflow obstruction benefit from quitting despite previous heavy smoking, advanced age, poor baseline lung function, or airway hyperresponsiveness.

UR - http://www.scopus.com/inward/record.url?scp=0034063821&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034063821&partnerID=8YFLogxK

M3 - Article

C2 - 10673175

AN - SCOPUS:0034063821

VL - 161

SP - 381

EP - 390

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 2 I

ER -